Anifrolumab was all-but written off in 2018 after failing the phase 3 TULIP-1 trial, but bounced back with positive data from a second study – TULIP-2 – that has proved sufficient for the FDA ...
AstraZeneca has been dealt a setback in attempts to rebuild its pipeline after anifrolumab lupus drug failed to reduce disease activity in a phase 3 trial. There was no word on whether AZ will ...
The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...
A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...
Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Lupus can do ...
Hosted on MSN22d
Anifrolumab Tied to Less Organ Damage for Patients With LupusTHURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback